CMS Issues New Specific ICD-10 Code K76. 82 with regard to HE

LAVAL, QC , Aug. 10, 2022 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its gastroenterology business, Salix Pharmaceuticals, (“Salix”), one of the largest specialty pharmaceutical companies in the world committed to the particular prevention and treatment associated with gastrointestinal (GI) and liver diseases plus disorders, today announced the support of the publication of a  new specific ICD-10 code from the Centers regarding Medicare & Medicaid Services (CMS) intended for hepatic encephalopathy (HE) based on the particular growing incidence of chronic liver disease in the United States.    

Approximately 4. 5 million adults in the U. S. have chronic liver organ disease 1 .   As chronic liver disease progresses towards decompensated cirrhosis, patients may develop comorbid conditions such as portal hypertension, ascites, and hepatic encephalopathy.   Up to 80% of people with cirrhosis may develop some form associated with HE 2 . HE is also a high driver of hospitalizations and readmissions in patients along with decompensated cirrhosis 3 .

The new K76. 82 diagnosis program code for individuals with HE, a complication of cirrhosis, is based on the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) plus announced by CMS to be used effective Oct. 1, 2022 .

The condition of HE can be misdiagnosed, and the availability of this new ICD-10 code will help health care providers properly document the particular diagnosis to get these sufferers and thus advance efforts to ensure their clinical management is appropriate.

To learn more about the Federal Register announcement please visit here .

About Salix
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies inside the world committed to the prevention and treatment of gastrointestinal (GI) plus liver diseases and disorders. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients’ lives plus arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line in order to U. S. healthcare providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists plus primary care. Salix is headquartered in Bridgewater, Brand new Jersey . For more information about Salix, visit   and connect along with us on Twitter   plus LinkedIn .

About Bausch Wellness
Bausch Health Companies Incorporation. (NYSE/TSX: BHC) is a global diversified pharmaceutic company whose mission will be to improve people’s lives with our medical care products. We create, manufacture and market a range associated with products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals plus eye health, through our own approximately 90% ownership of Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global wellness. For more information, check out   and connect with us on Twitter and LinkedIn .

Forward-looking Statements
This news release might contain forward-looking statements regarding Bausch Wellness, which may generally be identified simply by the use of the words “anticipates, ” “hopes, inch “expects, inches “intends, ” “plans, inch “should, inches “could, ” “would, inch “may, inches “believes, ” “subject to” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks plus uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition , actual results are subject in order to other risks and uncertainties that relate more broadly to Bausch Health’s overall business, including those a lot more fully described in Bausch Health’s filings with the Circumstance. S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance upon any of these forward-looking statements. These types of forward-looking statements speak only as of the particular date hereof. Bausch Health undertakes no obligation in order to update any of these forward-looking claims to reflect events or circumstances after the date of this particular news release or even to reveal actual outcomes, unless required by law.


1. Centers pertaining to Disease Control and Prevention. Chronic liver organ disease plus cirrhosis. Accessed April 19, 2022 .
2. Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in persistent liver illness: 2014 Practice Guideline simply by the American Association for the Study associated with Liver Illnesses and the European Association for that Study of the Liver. Hepatology. 2014; 60(2): 715-735.
3. C Chirapongsathorn S, Krittanawong C, Enders FT, et al. Incidence and cost analysis of hospital admission and 30-day readmission among patients with cirrhosis. Hepatol Commun. 2018; 2(2): 188-198. Published 2018 Jan 18. doi: ten. 1002/hep4. 1137

©2022 Salix Pharmaceutical drugs or the affiliates.
SAL. 0093. USA. 22

SOURCE Bausch Wellness Companies Inc.

Leave a Reply

Your email address will not be published.